INT110023

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2003
Last Reported 2011
Negated 3
Speculated 3
Reported most in Body
Documents 127
Total Number 130
Disease Relevance 84.27
Pain Relevance 45.42

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Mapk14) cell morphogenesis (Mapk14) response to stress (Mapk14)
cytoplasm (Mapk14) cytosol (Mapk14) nucleus (Mapk14)
Anatomy Link Frequency
microglia 3
macrophages 2
spinal 2
skin 2
muscle 2
Mapk14 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 2368 100.00 Very High Very High Very High
Spinal cord 452 100.00 Very High Very High Very High
dexamethasone 10 100.00 Very High Very High Very High
MU agonist 3 99.98 Very High Very High Very High
long-term potentiation 445 99.92 Very High Very High Very High
Neuropathic pain 1132 99.88 Very High Very High Very High
substance P 89 99.88 Very High Very High Very High
Infliximab 36 99.88 Very High Very High Very High
allodynia 361 99.80 Very High Very High Very High
COX-2 inhibitor 55 99.80 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 2873 100.00 Very High Very High Very High
Neuropathic Pain 1569 99.88 Very High Very High Very High
Asthma 790 99.88 Very High Very High Very High
Carcinoma 11 99.84 Very High Very High Very High
Respiratory Disease 8 99.84 Very High Very High Very High
Acantholysis 203 99.80 Very High Very High Very High
Pain 578 99.74 Very High Very High Very High
Targeted Disruption 343 99.70 Very High Very High Very High
Nociception 72 99.48 Very High Very High Very High
Diabetic Neuropathy 236 99.44 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Two doses of a selective p38 inhibitor, SCIO-469, were administered in the chow starting 5 days post-surgery and continued throughout the study.
Negative_regulation (inhibitor) of p38
1) Confidence 0.59 Published 2008 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 18584857 Disease Relevance 1.11 Pain Relevance 0.47
We have recently demonstrated a requirement for p38 MAPK signaling during preimplantation development by characterizing the reversible developmental blockade that occurs at the 8- to 16-cell stage following inhibition of MAPK14/p38?
Negative_regulation (inhibition) of p38 in 16-cell stage
2) Confidence 0.58 Published 2007 Journal BMC Dev Biol Section Body Doc Link PMC1781062 Disease Relevance 0.08 Pain Relevance 0
We have recently demonstrated a requirement for p38 MAPK signaling during preimplantation development by characterizing the reversible developmental blockade that occurs at the 8- to 16-cell stage following inhibition of MAPK14/p38?
Negative_regulation (inhibition) of MAPK14 in 16-cell stage
3) Confidence 0.58 Published 2007 Journal BMC Dev Biol Section Body Doc Link PMC1781062 Disease Relevance 0.08 Pain Relevance 0
Several p38 MAPK inhibitors including SB281838, BIRB0796, Ro320-1195, and SCIO-469 have been tested in clinical trials for inflammatory diseases such as rheumatoid arthritis as well as for cancer [67,68].
Negative_regulation (inhibitors) of p38 MAPK associated with inflammation, cancer, rheumatoid arthritis and disease
4) Confidence 0.53 Published 2007 Journal Mol Pain Section Body Doc Link PMC2186318 Disease Relevance 1.20 Pain Relevance 0.65
p38 inhibition and neuropathic pain
Negative_regulation (inhibition) of p38 associated with neuropathic pain
5) Confidence 0.53 Published 2007 Journal Mol Pain Section Body Doc Link PMC2186318 Disease Relevance 0.97 Pain Relevance 0.95
up-regulation is attenuated by spinal inhibition of p38 (Fig 2b).
Negative_regulation (inhibition) of p38 in spinal
6) Confidence 0.53 Published 2007 Journal Mol Pain Section Body Doc Link PMC2186318 Disease Relevance 0.63 Pain Relevance 0.63
However, further studies suggest that inhibition of p38 is also able to reverse neuropathic pain symptoms in different animal models [34,38,40,44,46].
Negative_regulation (inhibition) of p38 associated with neuropathic pain
7) Confidence 0.53 Published 2007 Journal Mol Pain Section Body Doc Link PMC2186318 Disease Relevance 1.39 Pain Relevance 1.30
Administration of a p38 inhibitor, SB203580, reverses p38-mediated pain in several pain models [9,14].
Negative_regulation (inhibitor) of p38 associated with pain
8) Confidence 0.50 Published 2010 Journal Mol Pain Section Body Doc Link PMC2881061 Disease Relevance 1.83 Pain Relevance 1.36
In addition, other p38 inhibitors are used with the same result [24].
Negative_regulation (inhibitors) of p38
9) Confidence 0.50 Published 2010 Journal Mol Pain Section Body Doc Link PMC2881061 Disease Relevance 0.48 Pain Relevance 0.95
Regardless, our findings support the use of p38 inhibitors for treating PDN of type 2 diabetes.
Negative_regulation (inhibitors) of p38 associated with painful diabetic neuropathy and diabetes mellitus
10) Confidence 0.50 Published 2010 Journal Mol Pain Section Body Doc Link PMC2881061 Disease Relevance 0.75 Pain Relevance 1.07
To determine directly if the activation of p38 mediates mechanical allodynia in db/db mice, a p38 inhibitor, SB203580, was administered intrathecally via mini osmotic pumps.
Negative_regulation (inhibitor) of p38 associated with allodynia
11) Confidence 0.50 Published 2010 Journal Mol Pain Section Body Doc Link PMC2881061 Disease Relevance 0.39 Pain Relevance 0.77
We found here for the first time that nerve injury produces a sustained and significant reduction in protein levels of phosphorylated-ERK and -p38 in cytosolic preparations of the mouse lower midbrain.
Negative_regulation (reduction) of p38 in midbrain associated with nervous system injury and midbrain
12) Confidence 0.50 Published 2004 Journal J. Neurochem. Section Abstract Doc Link 15009639 Disease Relevance 0.34 Pain Relevance 1.22
In contrast, i.c.v. treatment with a specific inhibitor of p38, SB203580, did not interfere with the morphine-induced rewarding effect.
Negative_regulation (inhibitor) of p38 associated with morphine
13) Confidence 0.50 Published 2004 Journal J. Neurochem. Section Abstract Doc Link 15009639 Disease Relevance 0.29 Pain Relevance 1.30
When inhibiting MAPKs using pharmacological inhibitors, we showed that p38MAPK inhibition abrogated the synergistic effect of APAP and LPS found for TNFalpha production but not for IL-1beta production.
Negative_regulation (inhibition) of p38MAPK associated with paracetamol
14) Confidence 0.50 Published 2009 Journal J Immunotoxicol Section Abstract Doc Link 19589095 Disease Relevance 0.27 Pain Relevance 1.32
and Vegf mRNA expression in TA muscle was significantly attenuated in p38?
Negative_regulation (attenuated) of p38 in muscle
15) Confidence 0.49 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2775956 Disease Relevance 0.07 Pain Relevance 0
When SB203580, a p38MAPK inhibitor, was added, RANKL mRNA and RANKL protein expression were increased in these cells.
Negative_regulation (inhibitor) of p38MAPK
16) Confidence 0.49 Published 2007 Journal Mol. Cell. Biochem. Section Abstract Doc Link 17549607 Disease Relevance 0.43 Pain Relevance 0.04
Unlike insulin, the effect of berberine on increasing glucose uptake was insensitive to wortmannin, an inhibitor of PI3K, and SB203580, an inhibitor of p38 MAPK [7].
Negative_regulation (inhibitor) of p38 MAPK
17) Confidence 0.48 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2952334 Disease Relevance 0.29 Pain Relevance 0
For instance, in human colonic carcinoma cells, inhibition of p38MAPK activity with SB203580 increased drug-induced apoptosis [64].
Negative_regulation (inhibition) of p38MAPK associated with carcinoma and apoptosis
18) Confidence 0.47 Published 2010 Journal BMC Complement Altern Med Section Body Doc Link PMC2999583 Disease Relevance 1.11 Pain Relevance 0
In addition, protein kinase C (PKC) inhibitors, 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H-7) and chelerythrine, significantly inhibited guanfacine-induced interleukin-12 production and p38 MAPK in a concentration-dependent manner.
Negative_regulation (inhibited) of p38 MAPK associated with kinase c
19) Confidence 0.46 Published 2003 Journal Eur. J. Pharmacol. Section Abstract Doc Link 12706479 Disease Relevance 0 Pain Relevance 0.60
Inhibitors of p38 MAPK prevented the stimulatory effects of alpha(2)-adrenoceptor agonists on IL-12 production.
Negative_regulation (Inhibitors) of p38 MAPK associated with agonist
20) Confidence 0.46 Published 2003 Journal Eur. J. Pharmacol. Section Abstract Doc Link 12706479 Disease Relevance 0 Pain Relevance 0.53

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox